CD274 and triple-negative breast carcinoma: The antibody (E1L3N) we used for PDL1 detection has been used and proved to have the highest positive rate in triple-negative breast cancer [35, 48]; it was not correlated with any PDL1/PD1 blockade drugs now and maybe overestimating PD-L1-positive tumors compared with FDA approved PDL1(SP142).